Lilly Asia Ventures

Lilly Asia Ventures (礼来亚洲基金, LAV) is an independent life-sciences and healthcare investment manager that traces its origins to Eli Lilly's corporate venture arm. According to 暗涌Waves, it spun out from the pharmaceutical company's risk-investment department and became a standalone firm in 2011, making it one of the earliest dedicated biotech funds focused on China's innovation market . It is now regarded as one of the leading corporate venture capital (CVC) players in the sector and serves as an important source of intelligence and product pipeline for Eli Lilly's own innovation efforts .

The fund appears actively in deal flow alongside other top-tier international investors. In March 2026 it participated in Aikelian Biotechnology's $27.7 million extension round alongside Matrix Partners China and Eisai Innovation, and in Syneron Bio's $150 million Series B alongside ADIA, Temasek's Daming Capital, and others . Its positioning in the market, as described by 暗涌, is that of a specialist fund with distinctive capabilities and resource coverage in medical and health industries .